Advanced Therapy Medicinal Products Market Size, Share, Trends, Growth Outlook

Advanced Therapy Medicinal Products Market is estimated to increase at a growth rate of 16.2% CAGR over the forecast period from 2024 to 2030.

The Advanced Therapy Medicinal Products Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Type (Cell Therapy, Stem Cell Therapy, Non-stem Cell Therapy, Gene Therapy, Tissue Engineered Product).

An Introduction to Advanced Therapy Medicinal Products Market in 2024

The Advanced Therapy Medicinal Products (ATMP) Market in 2024 is experiencing rapid growth, propelled by the emergence of innovative cell and gene therapies, regenerative medicine approaches, and personalized treatment modalities to address complex diseases and unmet medical needs. ATMPs represent a new frontier in biopharmaceutical innovation, leveraging advances in stem cell biology, genetic engineering, and tissue engineering to develop curative or disease-modifying therapies for rare genetic disorders, cancer, and degenerative conditions. With advancements in manufacturing technologies, regulatory frameworks, and clinical trial methodologies, the market offers a pipeline of ATMP candidates, including gene-modified cell therapies, tissue-engineered implants, and ex vivo gene editing platforms, targeting specific molecular targets and patient populations. Moreover, the integration of patient access programs, reimbursement strategies, and value-based care models further enhances market adoption, affordability, and sustainability of ATMPs, driving therapeutic innovation and transforming the landscape of regenerative medicine.

Advanced Therapy Medicinal Products Market Trend: Increasing Adoption of Cell and Gene Therapies

A prominent trend in the Advanced Therapy Medicinal Products (ATMPs) market is the accelerating adoption of cell and gene therapies for the treatment of various diseases. There is growing interest and investment in ATMPs due to their potential to provide curative or long-term therapeutic benefits for patients with genetic disorders, cancer, autoimmune diseases, and other severe conditions. Advancements in biotechnology, genetic engineering, and regenerative medicine have enabled the development of innovative ATMPs that harness the body's own cells or genetic material to target underlying disease mechanisms, leading to improved patient outcomes and reduced reliance on traditional treatments.

Advanced Therapy Medicinal Products Market Driver: Favorable Regulatory Environment and Supportive Policies

The primary driver fueling the Advanced Therapy Medicinal Products market is the establishment of a favorable regulatory environment and supportive policies by regulatory authorities worldwide. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Japan Pharmaceuticals and Medical Devices Agency (PMDA), have implemented expedited pathways, accelerated approval programs, and regulatory frameworks specifically tailored to facilitate the development and commercialization of ATMPs. These initiatives aim to streamline the regulatory review process, reduce market entry barriers, and incentivize investment in innovative therapies, fostering collaboration between industry stakeholders, academia, and regulatory bodies to advance the field of advanced therapies and bring transformative treatments to patients in need.

Advanced Therapy Medicinal Products Market Opportunity: Expansion of Manufacturing Capacity and Infrastructure

An opportunity in the Advanced Therapy Medicinal Products market lies in the expansion of manufacturing capacity and infrastructure to meet the growing demand for ATMPs and address manufacturing challenges associated with complex cell and gene therapy products. With the increasing number of ATMPs entering clinical development and nearing commercialization, there is a critical need for scalable and cost-effective manufacturing solutions capable of producing high-quality, consistent, and compliant products at commercial scale. Investing in advanced manufacturing technologies, automated production systems, and flexible manufacturing facilities can enable biopharmaceutical companies and contract manufacturing organizations (CMOs) to ramp up production, reduce manufacturing costs, and accelerate the availability of ATMPs to patients worldwide. Additionally, establishing strategic partnerships, collaborative networks, and knowledge-sharing platforms within the industry can foster innovation, drive process optimization, and address supply chain challenges, ultimately enhancing the accessibility and affordability of advanced therapies for patients globally.

Advanced Therapy Medicinal Products Market Segmentation

By Type
Cell Therapy
Stem Cell Therapy
Non-stem Cell Therapy
Gene Therapy
Tissue Engineered Product
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

 

Advanced Therapy Medicinal Products Market Companies

Bluebird Bio Inc
Celgene Corp
Gilead Lifesciences Inc
JCR Pharmaceuticals Co. Ltd
Kolon TissueGene Inc
MEDIPOST
Novartis AG
Organogenesis Inc
PHARMICELL Co. Ltd
Spark Therapeutics Inc
UniQure N.V.
Vericel Corp

 

 

Reasons to Buy the Advanced Therapy Medicinal Products Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Advanced Therapy Medicinal Products Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Advanced Therapy Medicinal Products Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

 

TABLE OF CONTENTS

1 Introduction to 2024 Advanced Therapy Medicinal Products Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Advanced Therapy Medicinal Products Market Size Outlook, $ Million, 2021 to 2030
3.2 Advanced Therapy Medicinal Products Market Outlook by Type, $ Million, 2021 to 2030
3.3 Advanced Therapy Medicinal Products Market Outlook by Product, $ Million, 2021 to 2030
3.4 Advanced Therapy Medicinal Products Market Outlook by Application, $ Million, 2021 to 2030
3.5 Advanced Therapy Medicinal Products Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Advanced Therapy Medicinal Products Market Industry
4.2 Key Market Trends in Advanced Therapy Medicinal Products Market Industry
4.3 Potential Opportunities in Advanced Therapy Medicinal Products Market Industry
4.4 Key Challenges in Advanced Therapy Medicinal Products Market Industry

5 Market Factor Analysis
5.1 Competitive Landscape
5.1.1 Global Advanced Therapy Medicinal Products Market Share by Company (%), 2023
5.1.2 Product Offerings by Company
5.2 Porter’s Five Forces Analysis

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Advanced Therapy Medicinal Products Market Outlook By Segments
7.1 Advanced Therapy Medicinal Products Market Outlook by Segments
By Type
Cell Therapy
Stem Cell Therapy
Non-stem Cell Therapy
Gene Therapy
Tissue Engineered Product

8 North America Advanced Therapy Medicinal Products Market Analysis And Outlook To 2030
8.1 Introduction to North America Advanced Therapy Medicinal Products Markets in 2024
8.2 North America Advanced Therapy Medicinal Products Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Advanced Therapy Medicinal Products Market size Outlook by Segments, 2021-2030
By Type
Cell Therapy
Stem Cell Therapy
Non-stem Cell Therapy
Gene Therapy
Tissue Engineered Product

9 Europe Advanced Therapy Medicinal Products Market Analysis And Outlook To 2030
9.1 Introduction to Europe Advanced Therapy Medicinal Products Markets in 2024
9.2 Europe Advanced Therapy Medicinal Products Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Advanced Therapy Medicinal Products Market Size Outlook By Segments, 2021-2030
By Type
Cell Therapy
Stem Cell Therapy
Non-stem Cell Therapy
Gene Therapy
Tissue Engineered Product

10 Asia Pacific Advanced Therapy Medicinal Products Market Analysis And Outlook To 2030
10.1 Introduction to Asia Pacific Advanced Therapy Medicinal Products Markets in 2024
10.2 Asia Pacific Advanced Therapy Medicinal Products Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Advanced Therapy Medicinal Products Market size Outlook by Segments, 2021-2030
By Type
Cell Therapy
Stem Cell Therapy
Non-stem Cell Therapy
Gene Therapy
Tissue Engineered Product

11 South America Advanced Therapy Medicinal Products Market Analysis And Outlook To 2030
11.1 Introduction to South America Advanced Therapy Medicinal Products Markets in 2024
11.2 South America Advanced Therapy Medicinal Products Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Advanced Therapy Medicinal Products Market size Outlook by Segments, 2021-2030
By Type
Cell Therapy
Stem Cell Therapy
Non-stem Cell Therapy
Gene Therapy
Tissue Engineered Product

12 Middle East And Africa Advanced Therapy Medicinal Products Market Analysis And Outlook To 2030
12.1 Introduction to Middle East and Africa Advanced Therapy Medicinal Products Markets in 2024
12.2 Middle East and Africa Advanced Therapy Medicinal Products Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Advanced Therapy Medicinal Products Market size Outlook by Segments, 2021-2030
By Type
Cell Therapy
Stem Cell Therapy
Non-stem Cell Therapy
Gene Therapy
Tissue Engineered Product

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Bluebird Bio Inc
Celgene Corp
Gilead Lifesciences Inc
JCR Pharmaceuticals Co. Ltd
Kolon TissueGene Inc
MEDIPOST
Novartis AG
Organogenesis Inc
PHARMICELL Co. Ltd
Spark Therapeutics Inc
UniQure N.V.
Vericel Corp

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Type
Cell Therapy
Stem Cell Therapy
Non-stem Cell Therapy
Gene Therapy
Tissue Engineered Product